Why Less Is More in Integrative Cancer Care

Almost every week, a patient hands me a list. A dewormer, an old antibiotic, a diabetes drug, and often a second page of supplements underneath it. Sometimes they have been taking everything on it for months and are telling me only now.

I understand the impulse completely, and I want to say so before anything else. When you have been told your cancer is advanced, the idea that a few inexpensive, decades-old medications might be quietly doing something powerful is deeply appealing, and that appeal is not built on nothing. Much of the laboratory work behind these compounds is genuinely interesting, which is exactly why the conversation deserves more care than it usually gets.

What follows is not an argument that you should sit still and hope. It is an argument that long stacks of repurposed drugs work against the one thing an integrative approach ought to give you, which is precision. When someone is fighting for their life, doing two or three things carefully beats doing ten things hopefully.

What the laboratory work can and cannot tell you

Cells growing in a Petri dish have no liver to clear a compound, no gut bacteria to disturb, and no immune system to injure. When a drug kills those cells, we have learned something worth knowing. But the next question decides whether any of it matters to a patient: can a living person actually reach the concentration that did the killing?

For ivermectin, the honest answer is probably not. The effects reported in cell studies appear in the low micromolar range, with one macrophage study putting the concentration that halved cell viability near 7 micromolar (Zhang et al., 2022). Now compare that with what circulates in a person. Healthy volunteers given a single 120 mg dose, roughly ten times the highest approved amount on a weight-adjusted basis, peaked at about 0.28 micromolar (Guzzo et al., 2002). That distance is not a technicality. It is the entire question.

Fenbendazole is a harder case, because the comparison cannot even be made. Cell work points to activity near 1 micromolar, but the compound dissolves poorly, absorbs erratically, and has never been through a human pharmacokinetic study. The only indirect evidence comes from trials of oxfendazole, a related compound the body partly converts back into fenbendazole, where it appeared as a minor back-metabolite at a small fraction of the parent drug’s level (An et al., 2019). Anyone handing you a milligram figure from a website is handing you a number never connected to a blood level in a human being.

None of this proves these compounds cannot help anyone. It does mean that reasoning from “it killed cancer cells in the lab” to “therefore I should take it” skips the step where the dose has to be reachable in a body without breaking something else.

The story everyone repeats, and the detail that changes it

When patients ask me about fenbendazole, they are almost always thinking of Joe Tippens, the Oklahoma businessman with widely metastatic small cell lung cancer and a prognosis measured in months, who took canine fenbendazole with vitamin E, curcumin, and CBD oil, and whose later scans came back clean.

I want to treat that story with respect, because the people repeating it are frightened and looking for hope. But one detail rarely survives the retelling. By his own account, as discussed in peer-reviewed analyses of how the story spread, he was simultaneously enrolled in a clinical trial of pembrolizumab at MD Anderson (Kim et al., 2022). Pembrolizumab produces lasting remissions in a subset of lung cancer patients, which is precisely why he was in that trial. When two things happen at once, and one is a proven immunotherapy, no honest observer can credit the other. That is the whole difference between an anecdote and evidence.

The liver is where the published harm keeps showing up

Of everything documented in humans, liver injury is the most consistent. In a phase 1 trial of mebendazole given with temozolomide for high-grade glioma, four patients at the highest dose developed grade 3 elevations in liver enzymes, which reversed once the dose was lowered or stopped (Gallia et al., 2021). Notice what that means. Even the human-approved cousin of fenbendazole, given under close supervision, produced significant liver toxicity.

The self-dosing cases are worse. A 65-year-old man with prostate cancer followed advice from an online support group, took veterinary fenbendazole and ivermectin daily for roughly three months, and arrived jaundiced with an ALT of 1,764 U/L. Formal causality assessment rated the anthelmintics as the highly probable cause (Powderly et al., 2026).

Now, the part that concerns me most is that it can cost you a treatment without ever making you seriously ill. When liver enzymes rise during cancer treatment, an obvious suspect is already waiting: immune-mediated hepatitis, which means high-dose steroids and frequently permanent discontinuation of immunotherapy. An 80-year-old woman stable on pembrolizumab for nine months developed liver injury after starting fenbendazole on her own. Because her team learned about it, they traced the cause correctly and kept her on the drug that was working (Yamaguchi et al., 2021). Had they not known, the chart would have recorded immunotherapy toxicity, and she would have lost it. Undisclosed use does not simply add a risk of its own. It corrupts every abnormal laboratory value that follows.

The complexity of drug and supplement interactions

Once several drugs and supplements are taken together, they stop behaving like separate decisions. Five things happen at once, none of them visible from the outside.

The first is competition for absorption. Compounds swallowed together crowd one another in the gastrointestinal tract, so less of what matters crosses the intestinal wall.

The second is albumin binding. Most drugs travel through the bloodstream attached to albumin and only the unbound fraction is active, so when too many substances compete for those binding sites, less of an anticancer compound reaches the tumor. Ivermectin runs about 93% protein-bound, and the researchers who first measured this warned decades ago to expect a higher free fraction wherever blood proteins fall (Klotz et al., 1990). Low albumin and muscle loss are the everyday conditions of advanced cancer, so a dose calibrated in healthy volunteers behaves quite differently in a patient thirty pounds lighter than last year.

The third is enzyme induction and inhibition. CYP3A4 clears a large share of oral cancer medications, and P-glycoprotein moves others in and out of cells. Repurposed agents act on the same machinery, and ivermectin, itself a CYP3A4 substrate, affects that pump in both directions. Whether chronic high-dose use raises or lowers the blood level of your targeted therapy is simply unknown, because nobody has measured it in patients.

The fourth is that a drug can quietly undo its own effect. Albendazole induces the very enzymes that clear it, and after four weeks of dosing, plasma concentrations of its active metabolite ran roughly 20% below those measured earlier in the same course (US Food and Drug Administration, 2009). The label number stays the same while your bloodstream exposure slips.

The fifth is that the combination itself cannot be predicted. How eight or ten active compounds behave together does not follow from what each does alone, and the result can be reduced effectiveness, increased side effects, or both.

Supplements sit inside all five of these, not outside them. The Tippens protocol pairs fenbendazole with high-dose vitamin E, which has real anticoagulant activity and raises bleeding risk in anyone with low platelets or on anticoagulation for a clot, along with curcumin and CBD, which occupy the same liver enzymes as the drugs.

What prolonged dosing does to the bone marrow

Benzimidazoles were designed for short courses, and the safety picture changes when they are taken continuously for months. Albendazole’s prescribing information warns of bone marrow suppression, aplastic anemia, and agranulocytosis, including reported deaths from granulocytopenia and pancytopenia, and requires blood counts at the start of each 28-day cycle and every two weeks during treatment (US Food and Drug Administration, 2019). Impaired liver function raises that risk, and it describes a great many people receiving cancer treatment.

Your gut remembers, and your immunotherapy depends on it

A diverse population of gut bacteria supports a working immune system and is one of the best predictors of whether immunotherapy will work. Patients who received antibiotics around the start of PD-1 blockade had shorter progression-free and overall survival (Routy et al., 2018).

The cost of disturbing that community runs longer than most people expect. When researchers linked stool samples from 2,509 Estonian adults to national prescription records, 167 of 186 analyzable medications, or 89.8%, were associated with the gut microbiome in some measurable way (Aasmets et al., 2025). Antibiotics were not the worst offenders. Beta-blockers explained more variation than any other class, with biguanides, the group that includes metformin, ranking third. Both appear constantly in repurposing protocols, so two of the most casually added agents are among the most disruptive in patients whose treatment depends on the very community being disrupted. I want to be careful here: this is no reason to stop a beta-blocker preventing a cardiac event or a metformin managing diabetes. It is a reason to review a list nobody has revisited in years.

The traces also outlast the prescription. For macrolides, penicillin combinations, benzodiazepines, and antidepressants, the signature remained detectable more than three years after the last dose, and past drug use explained more of a person’s current bacterial composition than current use did (Maier et al., 2018, found the same direction in laboratory screening, with roughly a quarter of drugs aimed at human targets inhibiting at least one gut species).

Why starving a tumor is harder than it sounds

The logic of metabolic restriction is appealing. Cancer cells consume glucose, glutamine, and fat with enthusiasm, so the obvious move is to cut the supply. The difficulty is that activated T cells, natural killer cells, and macrophages burn those same fuels, so a blockade that slows the tumor may also disarm the immune response you are counting on to finish the job.

The animal literature contains findings that deserve careful reading. Fenbendazole killed mouse lymphoma cells in culture, did nothing to tumors in animals, and left treated tumors expressing more PD-L1 and a larger share of immunosuppressive M2 macrophages (Jung et al., 2023). Researchers have filmed tumor cells drawing mitochondria out of neighboring T cells through fine nanotubes (Saha et al., 2022). A ketogenic diet shrank primary breast tumors in mice while accelerating metastasis through a protein called BACH1 (Su et al., 2024).

I will not overstate this. Each finding comes from a single preclinical study; other mouse work found no metastatic effect from ketogenic feeding, and small human trials reported acceptable safety with improved physical function (Cohen et al., 2018). What the collection establishes is that restriction is not a one-way street, and that a strategy which looks elegant on a whiteboard can point in the wrong direction inside a living body.

Muscle deserves separate mention. Cachexia accounts for somewhere near 20-30% of cancer deaths and cannot be reversed by eating more (Argilés et al., 2014). Imposing severe restriction and a heavy pill burden on a body already losing muscle risks accelerating the process most likely to end a patient’s life.

What a less-is-more approach actually looks like

None of this is an argument for doing nothing, and I want to be specific about the alternative. The best-supported addition to conventional treatment is not a compound at all. Supervised exercise during chemotherapy is safe across randomized trials and improves fitness, strength, fatigue, and quality of life. Around that, build a whole-food, low-glycemic, plant-predominant diet; enough protein and resistance work to hold onto muscle; real sleep; and repletion of deficiencies confirmed by testing. Comprehensive metabolic bloodwork shows where your body is struggling, and two or three interventions chosen from that picture will do more for you than twelve chosen from a forum.

The most valuable item on that list, and the one patients skip most often, is telling your oncology team everything you take. Among South Korean cancer patients who used non-prescription dewormers during chemotherapy, 96.5% never told their clinicians (Song et al., 2022), and in a United States survey, 29.3% of patients using complementary medicine did not disclose it, most often because nobody asked (Sanford et al., 2019).

Two further considerations belong in the decision. In May 2026, the American Society of Clinical Oncology issued a clinical notice stating that ivermectin and fenbendazole should not be used to treat cancer, or as an adjunct to established therapy, outside the safeguards of a well-designed clinical trial (American Society of Clinical Oncology, 2026). And among patients with curable cancers, those who chose alternative medicine instead of standard treatment had five-year survival of 54.7% compared with 78.3% (Johnson et al., 2018a), while a companion study found the excess mortality among complementary medicine users was explained by their higher rate of refusing or delaying conventional care (Johnson et al., 2018b). The danger in those studies was not the supplement. It was the delayed treatment.

The case for precision instead of volume

If broad restriction is a losing strategy, the alternative is a narrow intervention aimed at something structural, and here the biology is encouraging. Cardiolipin, the signature lipid of the inner mitochondrial membrane, is abnormal in tumor mitochondria, appearing in immature forms with defective remodeling (Kiebish et al., 2008). It also sits at the center of programmed cell death because, when oxidized in partnership with cytochrome c, it releases signals that take the cell apart (Kagan et al., 2005). A cell with a compromised membrane and depleted antioxidant reserves has far less capacity to absorb added oxidative stress than a healthy one.

That reasoning makes pro-oxidant approaches so promising, and the most encouraging clinical work I know comes from Dr. Alberto Izzotti and his colleagues. Rather than assembling a protocol, they added one agent, oral high-ozonide oil, to standard chemotherapy and radiotherapy in 115 patients and followed them for four years. Survival improved substantially, and relapses fell, and the benefit held even in the cancers that resist nearly everything we have, including glioblastoma and pancreatic adenocarcinoma.

What I find most compelling, though, is what did not happen. There was no immunosuppression. The protective T-helper and cytotoxic T lymphocyte populations were still standing at the end (Izzotti et al., 2022). That is the combination every patient is hoping for and the one that heavy drug stacks so reliably fail to produce: real pressure on the tumor, with the immune system intact to press the advantage. One compound, working with the body’s own machinery rather than against it, added to treatment that was already working.

These results come from an open clinical series rather than a randomized trial, which means the next step is a controlled study, not a final verdict. On the strength of what has been reported so far, that is a trial I would very much like to see run.

That same standard has to run in every direction. The case series most often cited as proof that fenbendazole produced remissions was retracted in 2026 over an undeclared conflict of interest (Retraction statement, 2026).

Intervening in a living system rarely leaves it exactly as it was found. We care for bodies that came with real protective systems already installed, and good stewardship looks less like overwhelming force than patient attention: fewer agents, better reasons, results you actually measure, and an oncology team that knows everything you are taking.

References

Why Less Is More in Integrative Cancer Care

Dr. Daniel Thomas, DO, MS